Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
231.96
-2.70 (-1.15%)
May 29, 2026, 4:00 PM EDT - Market closed
Ligand Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 274.48 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 | |
Revenue Growth (YoY) | 51.24% | 60.40% | 27.28% | -33.09% | -18.75% | 47.68% |
Cost of Revenue | 12.97 | 14.55 | 11.07 | 10.51 | 52.83 | 62.18 |
Gross Profit | 261.5 | 253.54 | 156.06 | 120.8 | 143.42 | 179.37 |
Selling, General & Admin | 94.48 | 92.45 | 78.65 | 52.79 | 70.06 | 46.79 |
Depreciation & Amortization Expenses | 32.55 | 32.71 | 32.96 | 33.65 | 34.24 | 34.22 |
Research & Development | 33.25 | 81.18 | 21.43 | 24.54 | 36.08 | 32.11 |
Other Operating Expenses | 6.64 | 6.2 | 45.63 | - | - | -37.6 |
Total Operating Expenses | 166.92 | 212.54 | 178.67 | 110.98 | 140.38 | 75.52 |
Operating Income | 94.59 | 41 | -22.61 | 9.82 | 3.04 | 103.85 |
Interest Income | 23.15 | 13.66 | 8.06 | 7.71 | 2.05 | 0.89 |
Interest Expense | -5.6 | -4.72 | -3.04 | -0.66 | -1.8 | -19.62 |
Other Non-Operating Income (Expense) | 90.3 | 117.96 | 25.12 | 51.72 | 32.97 | -31.65 |
Total Non-Operating Income (Expense) | 107.85 | 126.9 | 30.14 | 58.77 | 33.22 | -50.38 |
Pretax Income | 202.44 | 167.9 | 7.54 | 68.59 | 36.26 | 53.47 |
Provision for Income Taxes | -31.32 | -34.51 | -6.55 | -9.84 | -41.23 | 4.15 |
Net Income | 153.56 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Earnings From Discontinued Operations | - | - | - | -1.67 | -28.14 | -19.22 |
Net Income to Common | 153.56 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Shares Outstanding (Basic) | 20 | 19 | 18 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 20 | 20 | 18 | 18 | 17 | 17 |
Shares Change (YoY) | 9.33% | 10.96% | 3.00% | 5.27% | -2.19% | 2.50% |
EPS (Basic) | 7.84 | 6.44 | -0.22 | 3.02 | -0.31 | 3.44 |
EPS (Diluted) | 7.37 | 6.13 | -0.22 | 2.94 | -0.31 | 3.31 |
EPS Growth | - | - | - | - | - | 748.72% |
Shares Outstanding | 20.03 | 19.77 | 19.11 | 17.56 | 16.95 | 16.77 |
Free Cash Flow | 123.03 | 48.91 | 95.23 | 46.06 | 119.93 | 70.04 |
Free Cash Flow Growth | 151.56% | -48.64% | 106.76% | -61.60% | 71.23% | 39.72% |
Free Cash Flow Per Share | 6.03 | 2.41 | 5.21 | 2.59 | 7.11 | 4.06 |
Gross Margin | 95.27% | 94.57% | 93.37% | 91.99% | 73.08% | 74.26% |
Operating Margin | 34.46% | 15.29% | -13.53% | 7.48% | 1.55% | 42.99% |
Profit Margin | 85.17% | 46.42% | -2.41% | 40.98% | -2.66% | 31.61% |
FCF Margin | 44.82% | 18.24% | 56.98% | 35.07% | 61.11% | 29.00% |
EBITDA | 127.81 | 74.78 | 12.63 | 46.34 | 54.57 | 154.92 |
EBITDA Margin | 46.56% | 27.89% | 7.56% | 35.29% | 27.81% | 64.14% |
EBIT | 94.59 | 41 | -22.61 | 9.82 | 3.04 | 103.85 |
EBIT Margin | 34.46% | 15.29% | -13.53% | 7.48% | 1.55% | 42.99% |
Effective Tax Rate | -15.47% | -20.55% | -86.92% | -14.35% | -113.71% | 7.76% |